A genome-wide CRISPR/Cas9 screen for gain-of-function phenotypes increasing DC-mediated cross-presentation that employed gene-edited iniDC revealed that B-cell lymphoma 2 (BCL2) acts as an endogenous checkpoint to suppress cDC1-mediated tumor immunosurveillance. The gene discussed is BCL2; the disease is neoplasm.